

# **Bio-Solutions Corp. Announces the Signature of a Letter of Intent for the commercialization of GreenEx™ its main product targeting Malaria vectors in Democratic Republic of Congo.**

Montréal, Canada, December 8, 2009. Bio-Solutions Corp. (BISU, OTC:BB), is pleased to announce the signature of a Letter of Intent for the commercialization of GreenEx™ its main product targeting Malaria vectors in Democratic Republic of Congo.

Vice prime Minister of DRC in charge of country reconstruction, Emile Bongely confirmed to Bio-Solutions Corp. his agreement to evaluate GreenEx™ on site that will be targeted in December mission. Democratic Republic of Congo is facing two major health threats, Malaria and Typhoid fever. «Potential use of GreenEx™ in DRC will be the first important step in Malaria fighting process» said Dr. Chaumillon. Mission team will be in charge of site characterization for the pilot test and will determine the project scope as well as the spreading strategy. Our mission in DRC and meeting with government authorities will allow Bio-Solutions Corp. to determine primary parameters and frame of the financial agreement associated with this operation. «We are very proud to have this important opportunity so quickly in this high endemic area» mentioned Dr. Chaumillon.

GreenEx™ is an organic insecticide available in solid or liquid form which neutralizes and eradicates up to 98% of the larvae, within only 24 hours. Malaria is the most dangerous disease transmissible by mosquitoes that we know of. Each year, over 250 million people are infected worldwide of whom more than 5 millions in RDC.

For more information on Bio-Solutions Corp. and its products, please visit the company's website at [www.bio-solutionscorp.com](http://www.bio-solutionscorp.com)

## Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology industry, uncertainties related to the regulatory process and general

changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

**Contacts Investor & Public Relations**

Adrian McKenzie

(561) 654-5722

[pbdcllc@gmail.com](mailto:pbdcllc@gmail.com)